FDA Rejects Athenex’s Breast Cancer Treatment, Recommends Another Clinical Trial
On March 1st, New York-based Athenex Oncology, a global pharmaceutical company, announced receiving a complete response letter (CRL) from the FDA for its Encequidar. The agency expressed concern about the …
Read More